

USSN:10/776,934

Group Art Unit:1635

**Response to Restriction Requirement**

In the Notice of Non-Compliant Amendment dated April 20, 2006, the Examiner indicated that Applicants must elect a single species from claim 123. Applicants hereby elect dexamethasone.

Applicants respectfully submit that a generic claim directed to all chemotherapeutic compounds has been submitted, i.e., claim 122. Applicants respectfully submit that an election of a single species for search purposes under 35 U.S.C. 121 is more appropriate than the election of a single species for prosecution on the merits. Applicants understand that the claims will be restricted to this species, i.e., dexamethasone, if no generic claims is finally held allowable. Further, Applicants understand that upon the allowance of a generic claim, consideration will be given to the additional species as set forth in 37 C.F.R. 1.141 *et seq.*

USSN:10/776,934

Group Art Unit:1635

**CONCLUSION**

In view of the above amendment, Applicants believe that the pending application is in condition for allowance. If a telephonic conversation would be helpful, the Examiner is urged to contact the undersigned.

Dated: June 27, 2006

Respectfully submitted,

By   
Jonathan M. Sparks, F.M.B.

Registration No.: 53,624  
EDWARDS & ANGELL, LLP  
P.O. Box 55874  
Boston, Massachusetts 02205  
(617) 439-4444  
Attorneys/Agents For Applicant